Article Details

Halozyme scores $190M Horizon deal to develop subQ Tepezza formula

Retrieved on: 2020-12-01 17:36:55

Tags for this article:

Click the tags to see associated articles and topics

Halozyme scores $190M Horizon deal to develop subQ Tepezza formula. View article details on hiswai:

Excerpt

... just below the skin for high-volume delivery of <b>monoclonal antibodies</b> and other related drugs, company CEO Helen Torley said in an interview.

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up